ATRX and central nervous system cancer: In adults, wild-type IDH1 (wt-IDH1) glioma patients retain ATRX function, and typically present TP53 and TERTp mutations, and alterations in regulators of the receptor tyrosine kinase (RTK)-RAS-PI3K signaling cascade, including EGFR amplification and PTEN mutation or loss (Brennan et al., 2013; Louis et al., 2016; Masui et al., 2016; Reifenberger et al., 2017).